Carregant...
Pneumothorax following combination chemotherapy with bevacizumab: A case report and review of the literature
Bevacizumab (BV) is a humanized monoclonal antibody that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF). The addition of BV to combination chemotherapy has been shown to improve the outcomes in several malignancies, including colorectal carcinoma (CRC). However, the use...
Guardat en:
| Publicat a: | Mol Clin Oncol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
D.A. Spandidos
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6587012/ https://ncbi.nlm.nih.gov/pubmed/31281652 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2019.1868 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|